50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,640.47 (-2.11%)
DOW   29,225.61 (-1.54%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
S&P 500   3,640.47 (-2.11%)
DOW   29,225.61 (-1.54%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
S&P 500   3,640.47 (-2.11%)
DOW   29,225.61 (-1.54%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
S&P 500   3,640.47 (-2.11%)
DOW   29,225.61 (-1.54%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)

CorMedix - CRMD Stock Forecast, Price & News

$2.82
-0.19 (-6.31%)
(As of 09/29/2022 05:20 PM ET)
Add
Compare
Today's Range
$2.79
$3.09
50-Day Range
$2.85
$7.52
52-Week Range
$2.64
$8.02
Volume
122,260 shs
Average Volume
374,927 shs
Market Capitalization
$116.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

CorMedix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
393.0% Upside
$14.00 Price Target
Short Interest
Healthy
3.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.66mentions of CorMedix in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$18,424 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.83) to ($0.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

414th out of 1,096 stocks

Pharmaceutical Preparations Industry

187th out of 548 stocks

CRMD stock logo

About CorMedix (NASDAQ:CRMD) Stock

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

CRMD Stock News Headlines

CorMedix Inc. (CRMD)
CorMedix: Q2 Earnings Snapshot - Greenwich Time
Recap: Cormedix Q2 Earnings - Benzinga
Form 10-Q CorMedix Inc. For: Jun 30 - StreetInsider.com
See More Headlines
Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

CRMD Company Calendar

Last Earnings
8/11/2022
Today
9/29/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRMD
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+396.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,210,000.00
Net Margins
-25,202.44%
Pretax Margin
-25,678.05%

Debt

Sales & Book Value

Annual Sales
$190,000.00
Book Value
$1.65 per share

Miscellaneous

Free Float
39,725,000
Market Cap
$116.21 million
Optionable
Optionable
Beta
2.31

Key Executives

  • Dr. Matthew T. David M.D. (Age 44)
    Exec. VP & CFO
    Comp: $560.66k
  • Dr. Phoebe Mounts Esq. (Age 72)
    Exec. VP & Gen. Counsel
    Comp: $487.66k
  • Ms. Elizabeth Masson-Hurlburt B.A. (Age 43)
    EVP of Clinical & Medical Affairs
    Comp: $426.49k
  • Mr. Joseph Todisco MBA (Age 46)
    CEO & Director
  • Donna Ucci
    Sr. VP & Head of Global Quality













CRMD Stock - Frequently Asked Questions

Should I buy or sell CorMedix stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRMD shares.
View CRMD analyst ratings
or view top-rated stocks.

What is CorMedix's stock price forecast for 2022?

2 equities research analysts have issued 12 month price objectives for CorMedix's shares. Their CRMD share price forecasts range from $12.00 to $16.00. On average, they predict the company's share price to reach $14.00 in the next year. This suggests a possible upside of 384.4% from the stock's current price.
View analysts price targets for CRMD
or view top-rated stocks among Wall Street analysts.

How have CRMD shares performed in 2022?

CorMedix's stock was trading at $4.63 on January 1st, 2022. Since then, CRMD stock has decreased by 37.6% and is now trading at $2.89.
View the best growth stocks for 2022 here
.

When is CorMedix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CRMD earnings forecast
.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) posted its quarterly earnings data on Thursday, August, 11th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. The company had revenue of $0.02 million for the quarter. CorMedix had a negative net margin of 25,202.44% and a negative trailing twelve-month return on equity of 48.87%.

When did CorMedix's stock split?

CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL).

What is CorMedix's stock symbol?

CorMedix trades on the NASDAQ under the ticker symbol "CRMD."

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $2.89.

How much money does CorMedix make?

CorMedix (NASDAQ:CRMD) has a market capitalization of $119.10 million and generates $190,000.00 in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How can I contact CorMedix?

CorMedix's mailing address is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cormedix.com. The company can be reached via phone at 908 517 9500, via email at daniel@lifesciadvisors.com, or via fax at 908-429-4307.

This page (NASDAQ:CRMD) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.